Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS Less Than or Equal to 25 (RxFINE-Low)

NCT07391774 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07391774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07391774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS Less Than or Equal to 25 (RxFINE-Low)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Recruiting
Start date
August 10, 2026
Completion date
July 31, 2029
Enrollment
1,978 (estimated)
Sites
205

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage ii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, estrogen receptor-positive breast carcinoma, her2-negative breast carcinoma